Latest Intelligence on Pharmaceuticals and Healthcare in India

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Trauma devices: internal devices to grow fastest in India

Published By Datamonitor
03 May 2002
CommentWire
CommentWire

Ranbaxy: considers bid for Merck's generics unit

As the first company to express an interest in buying Merck's generics business, Ranbaxy has recognized that the acquisition would make it the world's third largest global generics player behind Teva and Novartis' Sandoz. However, the Indian-based company is likely to face competition from not only rival generics companies but also Big Pharma groups keen to diversify into the high-growth market.

Published By Datamonitor
10 Jan 2007
CommentWire
CommentWire

Pfizer: a triumph of the heart

Pfizer's share price has surged on news that the company has successfully defended two key Lipitor patents, deferring the threat of generic competition until 2011. This will enable Pfizer to proceed with plans to switch Lipitor patients to its controversial phase III torcetrapib and atorvastatin combination product before Lipitor is affected by generic competition, safeguarding its revenue stream.

Published By Datamonitor
20 Dec 2005
CommentWire
CommentWire

Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug

Novo Nordisk has suspended human trials of ragaglitazar, after discovering tumors in rodents that had been fed the experimental drug. The possible loss of ragaglitazar, which had been forecast peak annual sales of $1.78 billion, is Novo Nordisk's third setback this year. It also hits the drug's originator Dr Reddy's hard.

Published By Datamonitor
23 Jul 2002
CommentWire
CommentWire

Merck & Co: enters into R&D partnership with Ranbaxy

US-based Merck and India's biggest pharmaceutical company Ranbaxy have entered into an agreement to develop antibacterial and antifungal drugs. The deal highlights the trend of big pharmaceutical companies turning to India and China for R&D. As well as allowing Merck to develop its infectious disease portfolio, the agreement should provide valuable synergies for both companies.

Published By Datamonitor
13 May 2008
Expert View
Expert View

Indian pharmaceutical companies: innovative HIV drug reformulations

The FDA has tentatively approved new HIV drug co-formulations combining lamivudine, zidovudine (both originally developed by GSK) and nevirapine (by Boehringer Ingelheim) for use under the PEPFAR program. India's Cipla and Aurobindo, the manufacturers, have showed a remarkable creativity that may eventually pay off in high-price markets like the US and Europe.

Published By Datamonitor
08 Feb 2007
CommentWire
CommentWire

India: proposed profit controls threaten pharmaceutical strategy

A new discussion paper from the Indian government has proposed compulsory licensing for patented drugs. While this is unlikely to have a sizable impact given India's track record with patent rejections, the paper also mentions possible profit controls for drugs. These would certainly be more painful and would threaten branded pharmaceutical companies' expansion strategies into emerging markets.

Published By Datamonitor
02 Sep 2010
CommentWire
CommentWire

India: drug seizures dispute settled but concern remains over new trade agreement

The dispute between India and the European Union over recent seizures of Indian-made generics by a number of European countries has been settled before World Trade Organization action. However, Indian drug producers are growing increasingly concerned about the Anti-Counterfeiting Trade Agreement, and that it may allow seizures to become more commonplace.

Published By Datamonitor
12 Oct 2010
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

HIV drugs: India clears the path

Published By Datamonitor
12 Sep 2001

« | 1 | 2 | » »|

No help is available.